Vaccinex, Inc. financial data

Symbol
VCNX on OTC
Industry
Pharmaceutical Preparations
Location
1895 Mount Hope Ave, Rochester, NY
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Apr 15, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 78.5 % +11.5%
Return On Equity 1.86K % -3.75%
Return On Assets -434 % +24.1%
Operating Margin -3.12K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.68M shares +117%
Common Stock, Shares, Outstanding 2.68M shares +200%
Entity Public Float 5.58M USD -46.5%
Common Stock, Value, Issued 1K USD
Weighted Average Number of Shares Outstanding, Basic 2.1M shares +353%
Weighted Average Number of Shares Outstanding, Diluted 2.1M shares +353%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 601K USD
Research and Development Expense 12.5M USD -24.3%
General and Administrative Expense 6.79M USD -1.31%
Costs and Expenses 19.3M USD -17.6%
Operating Income (Loss) -18.7M USD +18.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -18.6M USD +7.99%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -18.6M USD +7.99%
Earnings Per Share, Basic -8.88 USD/shares +79.7%
Earnings Per Share, Diluted -8.88 USD/shares +79.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.11M USD -27.9%
Accounts Receivable, after Allowance for Credit Loss, Current 838K USD -12.8%
Assets, Current 2.53M USD -24.4%
Property, Plant and Equipment, Net 65K USD -52.2%
Operating Lease, Right-of-Use Asset 0 USD -100%
Assets 2.6M USD -28.5%
Accounts Payable, Current 3.96M USD +94%
Employee-related Liabilities, Current 223K USD -24.4%
Accrued Liabilities, Current 1.1M USD -11.1%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 5.08M USD -14.1%
Operating Lease, Liability, Noncurrent 21K USD -88.8%
Liabilities 5.08M USD -14.4%
Retained Earnings (Accumulated Deficit) -359M USD -5.48%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -2.49M USD -7.66%
Liabilities and Equity 2.6M USD -28.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.63M USD +8.1%
Net Cash Provided by (Used in) Financing Activities 6.07M USD +200%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 2.68M shares +200%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.44M USD
Deferred Tax Assets, Valuation Allowance 115M USD +5.45%
Deferred Tax Assets, Gross 115M USD +5.45%
Operating Lease, Liability 15K USD -92%
Depreciation 94K USD -21%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -18.6M USD +7.99%
Property, Plant and Equipment, Gross 7.25M USD +0.3%
Operating Lease, Liability, Current 0 USD -100%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 87 USD -98.9%
Deferred Tax Assets, Operating Loss Carryforwards 82.3M USD +4.86%
Preferred Stock, Shares Issued 10 shares
Preferred Stock, Shares Authorized 10M shares
Operating Lease, Payments 45.1K USD 0%
Preferred Stock, Shares Outstanding 10 shares
Share-based Payment Arrangement, Expense 341K USD -28.1%
Operating Leases, Future Minimum Payments Due 150K USD 0%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%